Do analysts rate COCP or CING?

Cingulate has a consensus price target of $27.00, suggesting a potential upside of 428.38%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, COCP or CING?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Cingulate N/A N/A -$22.45M -$3.59 N/A

Is COCP or CING more profitable?

Cocrystal Pharma's return on equity of -207.47% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Cingulate N/A -238.40% -128.67%

Which has higher valuation & earnings, ELOX or COCP?

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eloxx Pharmaceuticals N/A N/A -$5.99M -$1.54 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A

Is ELOX or COCP more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Cocrystal Pharma N/A -207.47% -123.33%

Do analysts rate MNOV or COCP?

MediciNova presently has a consensus target price of $8.33, indicating a potential upside of 478.70%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts clearly believe MediciNova is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer COCP or LONA?

Athira Pharma has a consensus price target of $17.33, indicating a potential upside of 128.37%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, COCP or LONA?

Athira Pharma is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A Athira Pharma N/A N/A -$105.61M -$4.21 N/A

Is COCP or LONA more profitable?

Cocrystal Pharma's return on equity of -207.47% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -207.47% -123.33% Athira Pharma N/A -411.58% -225.73%

Cocrystal Pharma (COCP) Competitors

$1.12 -0.04 (-3.45%)

As of 04:00 PM Eastern

Compare

COCP vs. VRCA, CING, ELOX, MNOV, and LONA

Should you buy Cocrystal Pharma stock or one of its competitors? Cocrystal Pharma's main competitors and comparable companies include Verrica Pharmaceuticals (VRCA), Cingulate (CING), Eloxx Pharmaceuticals (ELOX), MediciNova (MNOV), and Athira Pharma (LONA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Verrica Pharmaceuticals currently has a consensus target price of $12.67, indicating a potential upside of 141.73%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.53	-$17.89M	-$1.67	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than Cocrystal Pharma. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.89 beat Verrica Pharmaceuticals' score of 0.41 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Neutral
Cocrystal Pharma	Very Positive

Cocrystal Pharma has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Cocrystal Pharma's return on equity of -207.47% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Cocrystal Pharma	N/A	-207.47%	-123.33%

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Verrica Pharmaceuticals beats Cocrystal Pharma on 9 of the 15 factors compared between the two stocks.

How does Cocrystal Pharma compare to Cingulate?

Cocrystal Pharma (NASDAQ:COCP) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Cocrystal Pharma has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Cingulate has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 5.3% of Cingulate shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cocrystal Pharma's return on equity of -207.47% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Cingulate	N/A	-238.40%	-128.67%

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

In the previous week, Cingulate had 2 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Cingulate and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.89 beat Cingulate's score of -0.26 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Very Positive
Cingulate	Neutral

Cingulate has a consensus price target of $27.00, suggesting a potential upside of 428.38%. Given Cingulate's stronger consensus rating and higher possible upside, analysts plainly believe Cingulate is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cocrystal Pharma beats Cingulate on 7 of the 13 factors compared between the two stocks.

How does Cocrystal Pharma compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Cocrystal Pharma	N/A	-207.47%	-123.33%

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, suggesting a potential upside of 176.48%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Eloxx Pharmaceuticals and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.89 beat Eloxx Pharmaceuticals' score of 0.93 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Eloxx Pharmaceuticals	Positive
Cocrystal Pharma	Very Positive

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eloxx Pharmaceuticals has a beta of -1863.11, indicating that its share price is 186,411% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	N/A	N/A	-$5.99M	-$1.54	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Summary

Eloxx Pharmaceuticals beats Cocrystal Pharma on 8 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to MediciNova?

MediciNova (NASDAQ:MNOV) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, MediciNova had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.89 beat MediciNova's score of 0.88 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
MediciNova	Positive
Cocrystal Pharma	Very Positive

9.9% of MediciNova shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MediciNova has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

MediciNova presently has a consensus target price of $8.33, indicating a potential upside of 478.70%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts clearly believe MediciNova is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has lower revenue, but higher earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	172.87	-$12M	-$0.21	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Cocrystal Pharma has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Summary

MediciNova beats Cocrystal Pharma on 10 of the 16 factors compared between the two stocks.

How does Cocrystal Pharma compare to Athira Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Athira Pharma is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A

Athira Pharma has a consensus price target of $17.33, indicating a potential upside of 128.37%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Athira Pharma is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cocrystal Pharma has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 2.05, indicating that its share price is 105% more volatile than the broader market.

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cocrystal Pharma's return on equity of -207.47% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-207.47%	-123.33%
Athira Pharma	N/A	-411.58%	-225.73%

In the previous week, Athira Pharma had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Athira Pharma and 0 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.89 beat Athira Pharma's score of 0.94 indicating that Cocrystal Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cocrystal Pharma	Very Positive
Athira Pharma	Positive

Summary

Cocrystal Pharma beats Athira Pharma on 7 of the 13 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.57M	$12.09B	$7.13B	$12.68B
Dividend Yield	N/A	2.62%	2.54%	10.96%
P/E Ratio	-1.47	785.15	272.61	25.04
Price / Sales	N/A	759.90	612.80	95.93
Price / Cash	N/A	15.32	28.78	36.03
Price / Book	2.43	10.54	11.06	6.25
Net Income	-$8.83M	$2.82B	$3.47B	$348.99M
7 Day Performance	-0.88%	1.81%	-0.84%	-2.42%
1 Month Performance	36.59%	4.75%	7.15%	2.94%
1 Year Performance	-25.33%	9.07%	24.74%	13.69%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	1.7511 of 5 stars	$1.12 -3.4%	N/A	-22.7%	$22.34M	N/A	N/A	10	Positive News Gap Up
VRCA Verrica Pharmaceuticals	4.1521 of 5 stars	$4.94 +1.4%	$14.50 +193.5%	-2.3%	$83.66M	$35.58M	N/A	40
CING Cingulate	2.5216 of 5 stars	$5.87 +3.3%	$27.00 +360.0%	+29.6%	$82.60M	N/A	N/A	20	Analyst Upgrade
ELOX Eloxx Pharmaceuticals	2.8665 of 5 stars	$19.29 -3.5%	$41.50 +115.1%	N/A	$80.69M	$6.36M	N/A	N/A
MNOV MediciNova	1.8582 of 5 stars	$1.57 +2.6%	$8.33 +430.8%	+9.5%	$75.31M	$410K	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. VRCA, CING, ELOX, MNOV, and LONA

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Summary

How does Cocrystal Pharma compare to Cingulate?

Summary

How does Cocrystal Pharma compare to Eloxx Pharmaceuticals?

Summary

How does Cocrystal Pharma compare to MediciNova?

Summary

How does Cocrystal Pharma compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. VRCA, CING, ELOX, MNOV, and LONA

How does Cocrystal Pharma compare to Verrica Pharmaceuticals?

Which has more volatility and risk, VRCA or COCP?

Do analysts recommend VRCA or COCP?

Which has higher valuation & earnings, VRCA or COCP?

Does the media refer more to VRCA or COCP?

Is VRCA or COCP more profitable?

Do institutionals & insiders believe in VRCA or COCP?

Summary

How does Cocrystal Pharma compare to Cingulate?

Which has more risk and volatility, COCP or CING?

Do institutionals and insiders have more ownership in COCP or CING?

Is COCP or CING more profitable?

Which has higher valuation & earnings, COCP or CING?

Does the media refer more to COCP or CING?

Do analysts rate COCP or CING?

Summary

How does Cocrystal Pharma compare to Eloxx Pharmaceuticals?

Is ELOX or COCP more profitable?

Do analysts recommend ELOX or COCP?

Does the media favor ELOX or COCP?

Do insiders & institutionals have more ownership in ELOX or COCP?

Which has more volatility and risk, ELOX or COCP?

Which has higher valuation & earnings, ELOX or COCP?

Summary

How does Cocrystal Pharma compare to MediciNova?

Does the media prefer MNOV or COCP?

Do insiders and institutionals hold more shares of MNOV or COCP?

Which has more risk & volatility, MNOV or COCP?

Do analysts rate MNOV or COCP?

Which has higher earnings and valuation, MNOV or COCP?

Is MNOV or COCP more profitable?

Summary

How does Cocrystal Pharma compare to Athira Pharma?

Which has preferable earnings & valuation, COCP or LONA?

Do analysts prefer COCP or LONA?

Which has more volatility & risk, COCP or LONA?

Do institutionals & insiders believe in COCP or LONA?

Is COCP or LONA more profitable?

Does the media refer more to COCP or LONA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools